Literature DB >> 2439592

Recombinant interferon-alpha, -beta, and -gamma enhance the proliferative response of human B cells.

K Morikawa, H Kubagawa, T Suzuki, M D Cooper.   

Abstract

Recombinant interferons (IFN-alpha, -beta, and -gamma) were examined for their effects on B cell activation. Relatively small IgM+ B cells from human blood samples were isolated by fluorescence-activated cell sorting and were used as target cells. Although the interferons themselves were nonmitogenic, each enhanced the proliferative response induced by a mitogenic anti-mu monoclonal antibody, with IFN-beta usually showing the greatest enhancement and IFN-gamma the least. Pretreatment with the interferons primed resting B cells to undergo enhanced DNA synthesis in response to the anti-mu antibody DA4. Conversely, anti-mu pretreatment, followed by IFN treatment, did not induce B cells to enter the S phase. Time-course analysis revealed that IFN could augment the anti-mu response even when added as late as the final 24 hr of a 3-day culture interval. Combinations of IFN-gamma plus IFN-alpha or -beta were synergistic in the anti-mu response, whereas the IFN-alpha plus IFN-beta combination was not. The data suggest that interferons produced by both lymphocytes (IFN-gamma) and nonlymphoid inflammatory cells (IFN-alpha and -beta) can enhance B cell growth via different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439592

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice.

Authors:  Alexis Mathian; Mike Gallegos; Virginia Pascual; Jacques Banchereau; Sophie Koutouzov
Journal:  Eur J Immunol       Date:  2011-02-11       Impact factor: 5.532

2.  Effect of in vivo administration of recombinant murine gamma interferon on in vitro lymphoproliferative responses following immunization with Candida albicans.

Authors:  R E Garner; U Kuruganti; L A al-Hussaini; C W Czarniecki; J E Domer
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

Review 3.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15

4.  Major differences in the responses of primary human leukocyte subsets to IFN-beta.

Authors:  Anette H H van Boxel-Dezaire; Joana A Zula; Yaomin Xu; Richard M Ransohoff; James W Jacobberger; George R Stark
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

5.  Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response.

Authors:  Cristina L Swanson; Timothy J Wilson; Pamela Strauch; Marco Colonna; Roberta Pelanda; Raul M Torres
Journal:  J Exp Med       Date:  2010-06-21       Impact factor: 14.307

Review 6.  Genetic associations in type I interferon related pathways with autoimmunity.

Authors:  Angélica M Delgado-Vega; Marta E Alarcón-Riquelme; Sergey V Kozyrev
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

7.  Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus.

Authors:  Kanae Akita; Ken Yasaka; Tsuyoshi Shirai; Tomonori Ishii; Hideo Harigae; Hiroshi Fujii
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

8.  Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen.

Authors:  F Rousset; E Garcia; J Banchereau
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-α/γ-induced apoptosis.

Authors:  Mi Sun Park; Boh-Ram Kim; Sokbom Kang; Dae-Yong Kim; Seung Bae Rho
Journal:  Genes Cancer       Date:  2014-11

10.  Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2.

Authors:  T Defrance; B Vanbervliet; J P Aubry; J Banchereau
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.